Whilst we have raised the previosly estimated $2million required to obtain US Food and Drug Administration approval of the patented process for humans and to make the product available to our targeted markets our due diligence has been successfully completed and contracts now signed subject only to the remittance and clearance of funds. The new loan investment in the Company will allow trials to recommence.